Prolia (Denosumab) vs Evenity (Romosozumab): Real-World Evidence Comparison

How Each Drug Works: Different Mechanisms, Different Goals

Denosumab and romosozumab attack osteoporosis through completely different biological pathways. Denosumab is a fully human monoclonal antibody that binds RANK ligand (RANKL), blocking osteoclast formation, function, and survival to reduce bone resorption [1]. Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that normally suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation and decreases bone resorption, a so-called dual effect that no other approved agent replicates [2].

Denosumab: Pure Antiresorptive Action

Denosumab suppresses the RANKL pathway within days of injection. Serum C-terminal telopeptide (CTX), a resorption marker, falls by roughly 89% within 3 days of the first dose [1]. This rapid, deep suppression of resorption explains the drug's consistent fracture benefit across 10 years of the FREEDOM Extension study, where lumbar spine BMD continued to rise without plateau [3].

The mechanism also explains the drug's chief liability. Stop denosumab without bridging to another antiresorptive, and RANKL rebounds. Osteoclast activity surges above pre-treatment baseline, and multiple vertebral fractures can occur within 7 to 12 months of the last injection [4].

Romosozumab: Dual Anabolic and Antiresorptive Action

Sclerostin inhibition drives rapid, large increases in bone formation markers (P1NP rises roughly 145% by week 2) while simultaneously reducing resorption markers [2]. The net effect is a bone formation window that closes after approximately 12 months as the body partially compensates. This is why romosozumab is approved only for a single 12-month course [5].

After that window closes, consolidating the gains with denosumab or a bisphosphonate is not optional. Data from the ARCH trial show that patients who received romosozumab followed by alendronate had a 48% lower risk of new vertebral fracture compared with alendronate alone at 24 months [6].

Key Clinical Trials: What the Numbers Actually Show

The evidence base for both drugs is built on large, well-controlled Phase 3 programs with fracture endpoints. Real-world registry data published after initial approvals largely confirm those trial results.

FREEDOM Trial (Denosumab)

The FREEDOM trial enrolled 7,808 postmenopausal women with osteoporosis and randomized them to denosumab 60 mg SC every 6 months or placebo for 36 months [1]. Denosumab reduced new vertebral fractures by 68% (relative risk 0.32, 95% CI 0.26-0.41, P<0.001), hip fractures by 40%, and nonvertebral fractures by 20% [1].

The 10-year FREEDOM Extension followed 4,550 women who continued denosumab. Lumbar spine BMD increased 21.7% from the original baseline, and hip BMD increased 9.2%, with no evidence of an efficacy plateau [3]. Adverse event rates, including infection and malignancy, remained stable over the decade [3].

FRAME Trial (Romosozumab)

The FRAME trial enrolled 7,180 postmenopausal women randomized to romosozumab 210 mg SC monthly or placebo for 12 months, after which all patients received denosumab for 12 additional months [2]. At 12 months, romosozumab reduced new vertebral fractures by 73% vs placebo (P<0.001) and produced a 13.3% lumbar spine BMD gain vs 0.0% with placebo [2]. Clinical fracture risk fell 36% (P<0.001) [2].

At 24 months (after transition to denosumab in both groups), the romosozumab-then-denosumab group maintained a 75% lower vertebral fracture risk vs placebo-then-denosumab [2].

ARCH Trial (Romosozumab vs Alendronate)

ARCH is the most clinically consequential romosozumab trial because it compared the drug directly against an active comparator in 4,093 postmenopausal women with osteoporosis and prior fragility fracture [6]. Romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone at 24 months, and hip fracture risk by 38% [6].

ARCH also generated the safety signal that now defines romosozumab's label. Serious cardiovascular events (MI, stroke, cardiovascular death) occurred in 2.5% of the romosozumab group vs 1.9% of the alendronate group during the first 12 months [6]. The FDA added a boxed warning based on this finding [5].

Real-World Registry Evidence

A 2022 analysis of the International Osteoporosis Foundation (IOF) SCOPE registry examined denosumab persistence across 10 countries. Twelve-month persistence ranged from 51% to 92%, with lower persistence strongly associated with rebound fracture events [4]. A separate 2023 Japanese real-world cohort (N=1,240) comparing romosozumab to bisphosphonate sequential therapy found romosozumab patients achieved a 7.8% greater lumbar spine BMD gain at 12 months, consistent with FRAME [7].

BMD Gains: Head-to-Head Numbers

No published randomized trial has directly randomized patients to denosumab versus romosozumab. Network meta-analyses fill that gap.

A 2019 network meta-analysis published in the Journal of Bone and Mineral Research ranked treatments by lumbar spine BMD gain at 12 months across 30 trials [8]. Romosozumab ranked first with a mean 9.8% gain vs placebo, compared with 5.1% for denosumab and 3.1% for weekly alendronate [8]. At the femoral neck, romosozumab gained approximately 3.6% vs 2.9% for denosumab at 12 months [8].

These differences are clinically meaningful. Each 1% increase in femoral neck BMD corresponds to roughly a 3% reduction in hip fracture risk, based on pooled epidemiological data [9].

Safety Profiles: Where the Drugs Diverge Most

Both drugs share some class-level risks (hypocalcemia, osteonecrosis of the jaw, atypical femur fracture), but their distinct profiles diverge substantially on cardiovascular risk and rebound fracture.

Cardiovascular Risk (Romosozumab)

The FDA boxed warning states: "Romosozumab-aqqg may increase the risk of myocardial infarction, stroke, and cardiovascular death. Romosozumab-aqqg should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year" [5]. Clinicians should avoid romosozumab in patients with known cardiovascular disease, recent coronary intervention, or multiple cardiac risk factors.

The biological mechanism is not fully understood. Sclerostin may have a cardioprotective role in vascular tissue, and inhibiting it could alter vascular calcification pathways [10].

Rebound Fracture Risk (Denosumab)

Stopping denosumab without a bridging antiresorptive causes a well-documented rebound in bone resorption. A 2017 case series in Osteoporosis International described 13 patients who sustained multiple vertebral fractures within 7 to 16 months of the last denosumab dose [4]. The American Society for Bone and Mineral Research (ASBMR) 2022 task force report states: "Patients must be transitioned to an antiresorptive agent after denosumab discontinuation to prevent rapid bone loss and rebound fracture" [11].

Bisphosphonate bridging (typically zoledronic acid 5 mg IV, given 6 months after the last denosumab dose) reduces but does not eliminate rebound risk [11].

Shared Class Risks

Both agents carry a risk of osteonecrosis of the jaw (ONJ). Denosumab's ONJ risk in osteoporosis dosing is approximately 0.04% per patient-year in registry data, comparable to oral bisphosphonates [12]. Atypical femoral fractures occur at a rate of roughly 3.2 per 100,000 patient-years with denosumab in large pharmacovigilance analyses [12]. Hypocalcemia is more pronounced with romosozumab in patients who have vitamin D insufficiency; baseline 25-OH vitamin D should be above 30 ng/mL before starting either agent [13].

Switching Between Agents: The Sequential Therapy Question

Sequential therapy is now a standard clinical strategy for high-risk osteoporosis management. The order of drugs matters enormously for outcomes.

Romosozumab First, Then Antiresorptive

This is the evidence-backed sequence for patients who need rapid, large BMD gains. ARCH demonstrated that romosozumab (12 months) followed by alendronate (12 months) was superior to alendronate alone at 24 months on vertebral, hip, and nonvertebral fracture endpoints [6]. Similarly, FRAME showed romosozumab followed by denosumab maintained durable fracture protection at 24 months [2].

Starting with an anabolic or dual-action agent before consolidating with antiresorptive therapy follows the "anabolic first" principle endorsed by the Endocrine Society 2020 clinical practice guideline: "In patients at very high risk of fracture, anabolic therapy should be initiated first" [13].

Switching from Denosumab to Romosozumab

This direction is less studied. Because denosumab deeply suppresses bone remodeling, starting romosozumab immediately after denosumab may blunt the anabolic response. A small mechanistic study (N=18) published in JBMR in 2021 found that P1NP responses to romosozumab were attenuated for the first 3 to 6 months in patients transitioning from denosumab, compared with treatment-naive patients [14]. Waiting 3 to 6 months after the last denosumab dose may allow sufficient remodeling activity to restore a full romosozumab response, though this interval risks rebound bone loss [14].

Clinicians should weigh rebound fracture risk against the potential anabolic blunting. Patients with T-score below -3.0 who require a switch to romosozumab for inadequate BMD response may benefit from zoledronic acid as a brief bridge before initiating romosozumab, though this sequence lacks Phase 3 trial confirmation.

Switching from Romosozumab to Denosumab

After the 12-month romosozumab course, denosumab is a well-supported successor. FRAME used exactly this sequence, and 24-month data showed that BMD gains from romosozumab were fully preserved with subsequent denosumab [2]. Denosumab is preferred over oral bisphosphonates in patients with renal impairment (eGFR <35 mL/min/1.73m²), since bisphosphonates are contraindicated below that threshold [15].

Patient Selection: Which Drug for Which Patient

Selecting between denosumab and romosozumab comes down to fracture urgency, cardiovascular history, treatment duration intent, and patient adherence profile.

When to Choose Romosozumab

Romosozumab fits patients who need the largest possible BMD gain in the shortest time. A postmenopausal woman aged 70 with a T-score of -3.2, a recent vertebral fracture, and no history of MI or stroke is an archetype. The 12-month course produces a BMD gain roughly double that of denosumab in the same window, and the subsequent antiresorptive maintains the gain.

The Endocrine Society 2020 guideline designates romosozumab as a first-line option for patients at "imminent" fracture risk, defined as a recent fracture within the past 1 to 2 years, T-score below -3.0, or a 10-year FRAX hip fracture probability above 4.5% [13].

When to Choose Denosumab

Denosumab suits patients requiring long-term, consistent antiresorptive protection without the cardiovascular concern. Patients with established coronary artery disease, recent MI, or TIA within the past year should not receive romosozumab per the FDA label [5]. Denosumab also works in patients with chronic kidney disease (stages 3-5) where bisphosphonates are not appropriate [15].

Persistence matters. Denosumab requires reliable 6-month injection adherence. Missing a dose by more than 8 weeks creates a resorption gap that can trigger rebound, though the risk is lower than with full discontinuation [4].

Patients with Prior Bisphosphonate Therapy

Patients who have been on alendronate or risedronate for 3 or more years and show continued bone loss or fracture on therapy are candidates for escalation. Both romosozumab and denosumab are appropriate escalation targets. Romosozumab may be preferred if the patient tolerates no cardiac risk, since the anabolic window offers an opportunity to rebuild bone that bisphosphonates alone cannot provide [13].

Cost, Coverage, and Practical Administration

Both drugs are expensive. Denosumab (Prolia) carries a US average wholesale price near $1,900 per 60 mg prefilled syringe, administered twice yearly, for roughly $3,800 annually. Romosozumab (Evenity) costs approximately $1,900 per monthly injection, totaling near $22,800 for the full 12-month course. Medicare Part B covers both as provider-administered injections when medical necessity criteria are met [16].

Denosumab is administered subcutaneously in the upper arm, upper thigh, or abdomen. Romosozumab is given as two consecutive 105 mg subcutaneous injections at the same visit each month. Both are administered in a clinical setting or by a trained healthcare provider, not self-injected at home [5] [16].

Prior authorization requirements vary by payer. Most commercial plans require a documented T-score at or below -2.5 or a prior fragility fracture. For romosozumab, several payers additionally require failure or intolerance of at least one bisphosphonate [16].

Monitoring During and After Treatment

Bone turnover markers (BTMs) guide therapy response and help identify non-responders before the next scheduled DXA scan.

For romosozumab, P1NP should rise within 4 weeks of the first injection. A P1NP that fails to increase above baseline by 3 months may indicate poor adherence or a blunted anabolic response [13]. For denosumab, CTX should fall to near-undetectable levels by 1 month after each injection. A CTX that rises toward baseline between doses suggests a dosing interval problem [1].

DXA scanning at the lumbar spine and hip is recommended at baseline and again after 1 to 2 years of therapy for both agents [13]. A gain of less than 3% at the lumbar spine after 12 months of romosozumab or 24 months of denosumab warrants reassessment of secondary causes of bone loss (hyperparathyroidism, malabsorption, vitamin D deficiency) [13].

Calcium (1,000 to 1,200 mg/day total intake) and vitamin D (800 to 1,000 IU/day) supplementation is required with both drugs. Serum calcium should be checked within 2 weeks of the first dose of romosozumab in higher-risk patients [13].